Higher levels of miR-233 contained by EVs that are released by TAMs can be transported to the tumor cells of the breast, where they stimulate their invasiveness by the regulation of myocyte enhancer factor 2c (Mef2c)-β-catenin signaling cascade. This evidence concerns the gene MEF2C and neoplasm.